-
effectivehealthcare-admin.ahrq.gov/products/distributed-network-ambulatory-therapeutics/research
January 01, 2019 - This report comes at the end of the initial development phase of DARTNet. … In these practices the paper form is given to patients at the end of a visit for educational and personal … Structure
The DARTNet system is readily expandable, utilizing local parallel processing and a two stage … Other factors associated with adverse safety outcomes included renal dysfunction and certain specific … advent of new from on-going episodes of care, and track process and clinical outcomes within and at the end
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_surveillance.pdf
August 01, 2012 - Prevalence of pulmonary
hypertension in end-stage cystic fibrosis and
correlation with survival. … deficiency:
tumor in >80%
of cases
Not reported Retrospective cohort
study
Mean dose GH at the
end … Among particular
groups (e.g., Prader
Willi syndrome,
Turner Syndrome,
renal
insufficiency),
deaths … hypertension:61
confirmed cases;
most resolved with
discontinuation of
drug; increased risk
in Chronic Renal … In one controlled trial, mean Tanner
stage improved regardless of gender, and in
an analysis of three
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/distributed-network-ambulatory-therapeutics_research.pdf
July 01, 2009 - This report comes at the end of the initial development phase of DARTNet. … Structure
The DARTNet system is readily expandable, utilizing local parallel processing
and a two stage … Other factors associated with adverse safety outcomes included
renal dysfunction and certain specific … for the replication and propagation of DARTNet
should CINA’s involvement with DARTNet come to an end … to protect University of Minnesota and to allow for DARTNet to continue should their
involvement end
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/COVID-19-pharmaceutical-treatments-rapid-review.pdf
March 01, 2024 - Remdesivir
in COVID-19 Patients with End Stage Renal
Disease on Hemodialysis. … Evidence-based Practice Center (EPC) Program is developing a range of rapid evidence
products to assist end-users … RR = 0.34; CI: 0.01,
8.23
Wrist fracture: 0/1109,
1/1115
RR = 0.34; CI: 0.01,
8.23
Creatinine renal … Risk Factor Analysis
Risk of Bias (ROB)
Selvaraj, 202149
Remdesivir in
COVID-19 patients
with end … stage
renal disease
Letter to the editor
Setting: Inpatient
Cohort study
N = 28
Population:
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/arthritis_hi_impact.pdf
January 01, 2014 - noted that efficacy was demonstrated, they cited safety concerns about
infection, cardiovascular, and renal … times greater than the general population, and the substantial mortality is due primarily to comorbid
renal … Based on
this input, our overall assessment is that this intervention is in the
lower end of the … Committee form, EQ VAS quality of life score) were
obtained from the base-line evaluation to the end … The results remained stable from the end of the therapy to 6 months followup, before
significantly
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/autoimmune-disease-rapid-research.pdf
September 04, 2024 - The program has begun to develop a range of rapid evidence products to assist end
users in making specific … On one end of the spectrum, evidence inventories offer an
assessment of the quantity and type of evidence … On the other end,
rapid reviews adapt and streamline traditional systematic review methods to provide … At this stage, we excluded articles that did not describe dental
treatments, used healthy controls as … stage Renal disease (rePAIR): study protocol for a
randomized controlled trial
10.1186/s13063-
018
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/disparities-quality-improvement_executive.pdf
August 01, 2012 - )
– Hypertension
• Cystic fibrosis
• Depression (major depressive disorder only)
• Diabetes
• End-stage … renal disease
• Pneumonia (including pneumococcal vaccination)
• Pregnancy
Studies had to include data … review; second, descriptions of the
studies are organized by clinical condition as a reference
for end
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/01_arthritis_potential_high_impact_2012-12-10.pdf
January 01, 2012 - scores (IKDC form, EQ VAS
quality of life score) were reported between the baseline evaluation, the end … Barr virus-associated posttransplant lymphoproliferative disorder was
observed in patients who had renal
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/rapid-response-chemotherapy-dental.pdf
July 01, 2023 - oral or
dental examination performed on an inpatient basis as part of comprehensive workup prior to
renal … the body’s immune system, leading to impairment of resistance to infections
and other disorders.7 Renal … reviewer was unsure
regarding the appropriate disposition of a study (either at the abstract or full-text stage … Response, a thorough search of the MEDLINE database compiled all
relevant published studies through the end … Evidence-based Practice Center (EPC) Program using
streamlined literature review methods to assist end-users
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/ongoing-studies-evidence_research.pdf
December 01, 2010 - to suggest factors that might predict relevance and utility of
the completed study and associated end-products … when compared to the trial registration, and only 45 percent of studies were registered
before the end … While many of
these registries are no longer in existence, they likely set the stage for current clinical … Additionally, the time frame
20
examined in this project is at an early stage when trial registration … Type II Diabetes and the Metabolic Syndrome and on
Inflammatory Bowel Disease, Rheumatoid Arthritis, Renal
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/adhd-heart-disease-children_research.pdf
January 01, 2023 - other than non-melanoma skin cancer),
HIV infection, organ transplant, liver failure or hepatic coma, end-stage … renal disease, respiratory
failure, or severe congestive heart failure. … included to reduce the potential for misclassification and referred
to the first 30 days after the end … The former use category began after indeterminate use ended (i.e., at 31 days after end of
current use … of insurance
coverage/pharmacy benefit, day before 65th birthday, or end of study period (December
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/continuous-outcomes-quantitative-synthesis_methods.pdf
March 01, 2011 - The summary of final key points and
recommendations are presented in Table 2 at the end of this chapter … The two end points of IQR and range are
not symmetric around median (or mean) if the distribution of … Allowing
for uncertainty due to missing data in meta-
analysis--part 1: two-stage methods. … alter
the conclusions of a meta-analysis with
continuous outcomes: a case study of
changes in renal … monotherapy and
combination therapy with inhibitors of the
renin angiotensin system on proteinuria in
renal
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/tech-brief-37-opiod-use-adults-comments.pdf
November 03, 2020 - factors associated with opioid use, and
opioid-related harms and adverse outcomes are
included at the end … Next Steps Several future areas of research are identified at
the end of each section throughout the … assume long-term opioid use is
automatically bad, and because policymakers do
not always read to the end … I am now
at Stage II Renal Failure. … of ersatz
expected utility model you embrace- but you lack
the honesty to state clearly what your end
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/methodsguide_chou_assessing_harms_when_comparing.pdf
November 01, 2008 - outcomes
data, including data that showed no difference in gastrointestinal adverse events at the end … Development of instruments for assessing risk of bias specifically in studies of harms is still
in an early stage … Adverse Effects
of Cyclooxygenase 2 Inhibitors on Renal
and Arrhythmia Events: Meta-analysis of
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-guidance-harms_methods.pdf
November 01, 2008 - outcomes
data, including data that showed no difference in gastrointestinal adverse events at the end … Development of instruments for assessing risk of bias specifically in studies of harms is still
in an early stage … Adverse Effects
of Cyclooxygenase 2 Inhibitors on Renal
and Arrhythmia Events: Meta-analysis of
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/abnormal-uterine-bleeding_executive.pdf
March 01, 2013 - • Who are healthy, and without renal impairment,
hepatic impairment, intestinal disease, thyroid
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_surveillance.pdf
December 31, 2013 - pioglitazone at
baseline (228 mg/dl), and for placebo plus pioglitazone at baseline (236
mg/dl) and end … No clinically
significant changes in renal function. … Glimepiride(sulfo
nylureas) with
metformin RCT
68
normoalbuminuric
type 2 diabetes
patients 1 year
Renal … A total of 39.2 (exenatide)
vs. 20.8% (insulin) of patients reached the composite end point of A1C … Yale,
201345 Canagliflozin Placebo RCT
269 subjects with
type 2 diabetes and
stage 3 chronic
kidney
-
effectivehealthcare-admin.ahrq.gov/products/methods-guidance-harms/methods
May 01, 2020 - the outcomes data, including data that showed no difference in gastrointestinal adverse events at the end … Development of instruments for assessing risk of bias specifically in studies of harms is still in an early stage … Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/infantile-hemangioma_executive.pdf
January 01, 2016 - were
typically not severe, only one comparative study29
had greater than 6 months followup after the end … report use of steroids and laser treatments in younger
children with lesions in the proliferative stage … SACRAL syndrome:
spinal dysraphism, anogenital, cutaneous, renal and urologic
anomalies, associated
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/data-points-7-tables1.xls
August 25, 2011 - Ingredient, Age, Gender, and Race
Note: A dash signifies a small cell count (less than 11); ESRD = end … stage renal disease.